Research Topics
| Diego Garcia-BorregueroSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illnessDiego Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Mov Disord 17:934-41. 2002..Potential implications for the understanding of the relationship between RBD and PD are discussed...- Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndromeDiego Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Sleep 27:669-73. 2004.... - Restless legs syndrome: an overview of the current understanding and managementD Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Acta Neurol Scand 109:303-17. 2004..In conclusion, these and other recent findings shed light on our understanding and management of one of the most common movement disorders... - Correlation between rating scales and sleep laboratory measurements in restless legs syndromeDiego Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Sleep Disorders Unit, Universidad Autonoma de Madrid, Avda Reyes Catolicos 2, Madrid 28040, Spain
Sleep Med 5:561-5. 2004.... - L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessmentD Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
Neurology 61:1008-10. 2003..Mean sleep latency with L-dopa was 7 minutes, in contrast to a normal value of 19 minutes, 25 seconds with placebo. The authors' results suggest that L-dopa may cause daytime somnolence in some patients with Parkinson's disease... - Parkinson's disease and sleepDiego Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Sleep Med Rev 7:115-29. 2003..An adequate education of the PD patients in sleep hygiene measures and a skilled use of the medication seem necessary to prevent sleep disturbance... - Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over studyD Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
Neurology 59:1573-9. 2002..To assess the effects of gabapentin on sensory and motor symptoms in patients with restless legs syndrome (RLS)... - Circadian effects of dopaminergic treatment in restless legs syndromeDiego Garcia-Borreguero
Sleep Disorders Unit, Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Avda Reyes Catolicos 2, 28040 Madrid, Spain
Sleep Med 5:413-20. 2004..The reverse is also possible; dopaminergic medication might affect melatonin function, a key element of the circadian system. The present study investigated the effects of dopaminergic medication on melatonin secretion in RLS... 
Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeksDiego Garcia-Borreguero
Sleep Research Institute, Madrid, Spain
Mov Disord 27:277-83. 2012..The incidence of augmentation was 3.1% higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study...- Epidemiology of restless legs syndrome: the current statusDiego Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
Sleep Med Rev 10:153-67. 2006..In summary, epidemiological evidence suggests that RLS is a common neurological disorder-with high impact on many aspects of the life of those affected... - Time to REST: epidemiology and burdenDiego Garcia-Borreguero
Sleep Research Institute, Madrid, Spain
Eur J Neurol 13:15-20. 2006..Given the significant burden of morbidity associated with RLS, there is a strong case for treatment in patients with troublesome symptoms... - Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response studyDiego Garcia-Borreguero
Department of Neurology, Fundacion Jimenez Diaz, Sleep Disorders Unit, Universidad Autonoma de Madrid, Madrid, Spain
Sleep Med 8:119-27. 2007..To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS)... - European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research SocietyDiego Garcia-Borreguero
Sleep Research Institute, Madrid, Spain
Eur J Neurol 19:1385-96. 2012..These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society... 
Algorithms for the diagnosis and treatment of restless legs syndrome in primary careDiego Garcia-Borreguero
Sleep Research Institute, Madrid, Spain
BMC Neurol 11:28. 2011..Restless legs syndrome (RLS) is a neurological disorder with a lifetime prevalence of 3-10%. in European studies. However, the diagnosis of RLS in primary care remains low and mistreatment is common...- Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndromeDiego Garcia-Borreguero
Fundacion Jimenez Diaz, Madrid, Spain
Sleep Med 8:455-63. 2007..The changes in each dimension are summed to give an ASRS total score... - Fluctuations in cognition and alertness in Parkinson's disease and dementiaCarolina Serrano
Sleep Disorders Unit, Department of Neurology, Jimenez Diaz Foundation, Universidad Autonoma de Madrid, Avda Reyes Catolicos 2, 28040 Madrid, Spain
Neurology 63:S31-4. 2004..Other therapies, such as melatonin or modafinil, require further investigation... - Restless legs syndrome and PD: a review of the evidence for a possible associationDiego Garcia-Borreguero
Department of Neurology, , , Madrid, Spain
Neurology 61:S49-55. 2003..Therefore, neuronal degeneration in other dopaminergic pathways than the nigrostriatal might be relevant in the pathogenesis of RLS in PD... - Dopaminergic augmentation of restless legs syndromeDiego Garcia-Borreguero
Sleep Research Institute, Alberto Alcocer 19, Madrid, Spain
Sleep Med Rev 14:339-46. 2010..RLS is treated by maintaining low doses of dopaminergic agents and ensuring iron sufficiency. Non-dopaminergics and opiates can be used when patients experience augmentation with more than one dopaminergic agent... - A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndromeDiego Garcia-Borreguero
Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
Sleep Med 8:742-52. 2007..To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks... - Augmentation: understanding a key feature of RLSDiego Garcia-Borreguero
Sleep Med 5:5-6. 2004 - The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study GrouMarco Zucconi
Sleep Disorders Center, San Raffaele Hospital, Milano, Italy
Sleep Med 7:175-83. 2006 - Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in EuropeWolfgang H Oertel
Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, D 35039 Marburg, Germany
Sleep Med 9:228-39. 2008..In a pilot placebo-controlled study, low dosages of 0.5-2mg/24h rotigotine showed a dose-dependent beneficial effect in restless legs syndrome (RLS) patients... - Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trialClaudia Trenkwalder
Paracelsus Elena Hospital, Kassel, Germany
Lancet Neurol 7:595-604. 2008..Continuous administration of a dopamine agonist could be used to treat patients with restless legs syndrome. Our aim was to investigate the efficacy of transdermal rotigotine in the treatment of idiopathic restless legs syndrome... - Tireless work on restless legs: guest editors' introductionClaudia Trenkwalder
Paracelsus-Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr. 16, 34128 Kassel, Germany
Mov Disord 22:S393-4. 2007 - The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial settingLinda Abetz
Mapi Values, Adelphi Mill, Grimshaw Lane, Bollington, Cheshire SK10 5JB, UK
Sleep Med 7:340-9. 2006..0), using pooled data from two matching, placebo-controlled studies of ropinirole for treating Restless Legs Syndrome (RLS)... - Clinical trials in restless legs syndrome--recommendations of the European RLS Study Group (EURLSSG)Claudia Trenkwalder
Paracelsus Elena Hospital, Center of Parkinsonism and Movement Disorders, Klinikstr 16, 34128 Kassel, Germany
Mov Disord 22:S495-504. 2007..The aim of these recommendations is to support research groups or pharmaceutical companies in the design of optimized study protocols... - Assessment of restless legs syndrome--methodological approaches for use in practice and clinical trialsRalf Kohnen
IMEREM Institute for Medical Research Management, Biometrics Ltd, University of Erlangen Nuremberg, Nuremberg, Germany
Mov Disord 22:S485-94. 2007....